Lipodystrophy, Familial Partial clinical trials
The registry lists 20 studies for Lipodystrophy, Familial Partial across more than 10 countries. 5 are recruiting or about to start. 16 of them are mainly about Lipodystrophy, Familial Partial (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27.
Get an email when these change. Save the Lipodystrophy, Familial Partial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Centre Hospitalier Universitaire de la Réunion (3) · Regeneron Pharmaceuticals (3) · Assistance Publique - Hôpitaux de Paris (2) · Akcea Therapeutics (2) · University of Michigan (1) · Cambridge University Hospitals NHS Foundation Trust (1) · University Hospital, Lille (1) · Mayo Clinic (1)
What is being tested here
Drugs under test in Lipodystrophy, Familial Partial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Mibavademab | 1 | 2 | 3 |
| Metreleptin | 1 | 1 | 2 |
| Obeticholic acid | 0 | 0 | 1 |
| Vupanorsen | 0 | 0 | 1 |
| Gemcabene | 0 | 0 | 1 |
| ISIS 304801 | 0 | 1 | 1 |
| Caffeine | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Aug 2027Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study · Assistance Publique - Hôpitaux de Paris
Who these studies take
Of the 4 Lipodystrophy, Familial Partial studies recruiting now, 3 (75%) set no upper age limit and 1 (25%) stop at 75 or younger. 3 (75%) take children under 18. 1 (25%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (50%) | 2 (50%) |
| 18 | 4 (100%) | 3 (75%) |
| 30 | 4 (100%) | 3 (75%) |
| 40 | 4 (100%) | 3 (75%) |
| 50 | 3 (75%) | 3 (75%) |
| 65 | 3 (75%) | 3 (75%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 3 (75%) | 3 (75%) |
Across all 20 studies, recruiting or not: 15% stop at 75 or younger and 10% at 65; 35% take children; 10% are for women only and 5% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyRecruitingNCT07220785Phase 33 countries
- Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control StudyNot yet recruitingNCT077990121 country
- Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)RecruitingNCT07412028Not applicable1 country
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingNCT06679270Phase 31 country
- Registry for Patients With LipodystrophyRecruitingNCT0355342016 countries
- Low Energy Diet and Familial Partial LipodystrophyCompletedNCT03900286Not applicable1 country
- Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island SubjectsCompletedNCT06107439Not applicable1 country
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)CompletedNCT06548100Phase 31 country
- Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2CompletedNCT048451651 country
- A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)TerminatedNCT05088460Phase 24 countries
- The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.CompletedNCT070906291 country
- Phase 2 Study of Obeticholic Acid for Lipodystrophy PatientsCompletedNCT02430077Phase 21 country
- Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's LipodystrophyCompletedNCT05424913Not applicable1 country
- Familial Partial Lipodystrophy StudyCompletedNCT02858830Not applicable1 country
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial LipodystrophyTerminatedNCT02527343Phase 2/37 countries
- Lipodystrophy and Fat Metabolism During ExerciseWithdrawnNCT04056000Not applicable1 country
- Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)CompletedNCT03514420Phase 21 country
- CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyCompletedNCT02654977Phase 21 country
- Study of Gemcabene in Adults With FPLDCompletedNCT03508687Phase 1/21 country
- Lipodystrophy Connect Patient RegistryCompletedNCT025779521 country